Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

AI in Biopharmaceutical Development Market worth $16.4 Billion by 2030 - Exclusive Report by InsightAce Analytic

This image opens in the lightbox

News provided by

InsightAce Analytic Pvt. Ltd.

26 May, 2022, 11:30 GMT

Share this article

Share toX

Share this article

Share toX

JERSEY CITY, N.J., May 26, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global AI in Biopharmaceutical Development Market (Type (Monoclonal Antibodies, Vaccines, Recombinant Proteins), Application (Research And Discovery, Clinical Development, Manufacturing & Supply Chain And Other Subsegments), End-user (Biopharmaceutical manufacturers, Contract manufacturing organizations (CMOs) or contract research organizations (CROs), Academic & government research institutes))- Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

According to the latest research by InsightAce Analytic, the Global AI in Biopharmaceutical Development Market is valued at US$ 452.33 Million in 2021, and it is expected to reach US$ 16441.32 Million by 2030, with a CAGR of 49.3% during the forecast period of 2022-2030.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1227 

Artificial intelligence (AI) has emerged as the frontier technology most likely to have a breakthrough impact on the biopharmaceutical sector. Reasoning, knowledge representation, solution search, and machine learning are AI approach domains (ML) examples. It can aid in rational drug development, decision-making, choosing the optimum treatment for a patient, tailoring medicines, and maintaining clinical data for future drug development. AI can distinguish between hit and lead compounds in drug discovery, allowing speedier therapeutic target confirmation and structural design optimization. The FDA (United States Food and Drug Administration) has issued recommendations and launched many efforts to encourage the use of AI in the drug discovery and development process.

Artificial intelligence is becoming more popular in the biopharmaceutical industry, leading to market expansion. Additionally, rising drug research costs and increased knowledge of AI's ability to work are key factors driving market growth in the coming years. The market's growth is also being driven by a low failure rate of trials, and an abundance of software developers for drug discovery, and high demand for the software among big pharma & biotech companies and research institutes. Adopting AI solutions in the clinical trial process eliminates potential obstacles, reduces clinical trial cycle time, and improves productivity and accuracy.

The higher cost of AI-based equipment, its applications, & software is the most notable challenges in this AI-based biopharmaceutical development market. Apart from this, a lack of data sets in drug discovery, the unavailability of skilled employees and the absence of regulations and ethics for using artificial intelligence in healthcare are market restraints for the forecasting period. Because of the growing software and services industries and funding for their development, Asia Pacific is anticipated to gain prominence in the forecasting period 2022-2030.

Enquire Before Buying: https://www.insightaceanalytic.com/report/global-ai-in-biopharmaceutical-development-market-/1227 

Prominent market players in the AI in the Biopharmaceutical development market are IBM Watson Health, Google (Alphabet Inc.), Concreto HealthAI, Nvidia Corporation, PathAI, Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Inc., Ai-biopharma S.A.S., and Microsoft Corporation, among others, are some key players operating in the AI in Biopharmaceutical Development Market.

Key Developments in the market

  • In Apr 2021, Microsoft focused on healthcare AI with a $19.7B Nuance acquisition Microsoft will shell out $19.7 billion cash for Nuance. With Nuance's speech recognition and conversational AI software under its umbrella, Microsoft will expand its push to bring cloud-based AI tools to the healthcare industry on a broader scale.
  • In Apr 2021, Nvidia collaborated with AstraZeneca, the University of Florida, on AI-driven drug discovery. This collaboration will build a model trained using Nvidia DGX SuperPOD, an AI supercomputer, that will allow researchers to evaluate billions of molecules for potential drug candidates faster.
  • In Jan 2020, Concerto HealthAI announced an expansion of their existing Precision Oncology collaboration with Pfizer Oncology. The partnership is to advance Concerto HealthAI's use-case engineered Real-World Data (RWD) for various clinical development initiatives across breast, lung, prostate and renal cell carcinoma cancers, which will drive innovative new study designs non-interventional studies.
  • In Oct 2019, Novartis and Microsoft announced a collaboration to transform medicine with artificial intelligence. Novartis to establish an AI innovation lab to empower its associates to use AI across the business. Joint research activities will include co-working environments on Novartis Campus in Switzerland, Novartis Global Service Center in Dublin, and Microsoft Research Lab, tackling personalized therapies for macular degeneration, cell & gene therapy, and drug design.

Market Segments

Global AI in Biopharmaceutical Development Market , by Type, 2022-2030 (Value US$ Mn)

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins

Global AI in Biopharmaceutical Development Market , by Application, 2022-2030 (Value US$ Mn)

  • Research And Discovery
  • Clinical Development
  • Manufacturing & Supply Chain And Other Subsegments

Global AI in Biopharmaceutical Development Market , by End-user, 2022-2030 (Value US$ Mn)

  • Biopharmaceutical manufacturers
  • Contract manufacturing organizations (CMOs) or contract research organizations (CROs)
  • Academic & government research institutes

Global AI in Biopharmaceutical Development Market , by Region, 2022-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America AI in Biopharmaceutical Development Market , by Country, 2022-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe AI in Biopharmaceutical Development Market , by Country, 2022-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific AI in Biopharmaceutical Development Market , by Country, 2022-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America AI in Biopharmaceutical Development Market , by Country, 2022-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa AI in Biopharmaceutical Development Market , by Country, 2022-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

For Customization @ https://www.insightaceanalytic.com/customisation/1227

Other Related Reports Published by InsightAce Analytic:

Global Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market

Global Clinical Trials Software Market

Global Oncology Informatics Market

Why should one buy this report:

  • To receive a comprehensive analysis of the prospects for the Global AI in Biopharmaceutical Development Market
  • To receive an industry overview and future trends of the AI in Biopharmaceutical Development market
  • To analyze the AI in Biopharmaceutical Development Market drivers and challenges
  • To get information on the AI in Biopharmaceutical Development Market size (Value US$ Mn) forecast to 2030
  • Significant investments, mergers & acquisitions in the AI in Biopharmaceutical Development Market industry

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:

Priyanka Tilekar
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Email: info@insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.